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ABSTRACT 23 
Inositol levels, maintained by the biosynthetic enzyme inositol-3-phosphate synthase (Ino1), are 24 
altered in a range of disorders including bipolar disorder and Alzheimer’s disease. To date, most 25 
inositol studies have focused on the molecular and cellular effects of inositol depletion without 26 
considering Ino1 levels. Here we employ a simple eukaryote, Dictyostelium, to demonstrate 27 
distinct effects of loss of Ino1 and inositol depletion. We show that loss of Ino1 results in inositol 28 
auxotrophy that can only be partially rescued by exogenous inositol. Removal of inositol 29 
supplementation from the ino1- mutant results in a rapid 56% reduction in inositol levels, 30 
triggering the induction of autophagy, reduced cytokinesis and substrate adhesion. Inositol 31 
depletion also caused a dramatic generalised decrease in phosphoinositide levels that was rescued 32 
by inositol supplementation. However, loss of Ino1 triggered broad metabolic changes consistent 33 
with the induction of a catabolic state that was not rescued by inositol supplementation. These 34 
data suggest a metabolic role for Ino1 independent of inositol biosynthesis. To characterise this 35 
role, an Ino1 binding partner containing SEL1L1 domains (Q54IX5) was identified with 36 
homology to mammalian macromolecular complex adaptor proteins. Our findings therefore 37 
identify a new role for Ino1, independent of inositol biosynthesis, with broad effects on cell 38 
metabolism. 39 
 40 
INTRODUCTION 41 
Myo-inositol, a stereoisomer of inositol, is present in a variety of cell types and is obtained from 42 
three major sources: de novo synthesis from glucose-6-phosphate, sequential dephosphorylation 43 
of phosphoinositides, or membrane transport from extracellular fluid (15). Disruption of inositol 44 
homeostasis has been associated with a number of illnesses, including bipolar disorder 45 
(3,4,61,74), Alzheimer’s disease (2,41,68,72), bulimia (26), metabolic syndrome (39), diabetes 46 
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(30,52), and epilepsy (7). Understanding the cellular and metabolic changes resulting from 47 
inositol depletion will provide insight into the mechanisms underlying these diseases. 48 
Inositol-3-phosphate synthase (Ino1, EC 5.5.1.4) is crucial in the de novo biosynthesis of inositol, 49 
as an isomerase that converts glucose-6-phosphate to inositol-3-phosphate, which is then 50 
dephosphorylated to inositol (33)(Fig 1A). Inositol is an essential precursor of a large family of 51 
phosphoinositides (14), with one of these, phosphoinositide 4,5 bisphosphate (PIP2), used in the 52 
production of inositol phosphates. These molecules are important for a range of cellular functions, 53 
including motility (42), activation of signal transduction pathways (18), membrane trafficking 54 
and vesicular transport (15), protein secretion, and transcriptional regulation (62). Despite these 55 
broad functions, few studies have compared the physiological effects of reducing inositol levels 56 
and reducing Ino1 levels, therefore it remains unclear if these two effects have distinct roles. 57 
Dictyostelium discoideum is a single-celled eukaryote found in forest soils, where it survives by 58 
consuming bacteria. Dictyostelium is used as a research model in a variety of disciplines including 59 
biomedicine. We previously employed Dictyostelium in a 3Rs approach (animal reduction, 60 
replacement and refinement) for biomedical research, to investigate the effects of epilepsy 61 
treatments on modulating phosphoinositide signalling and seizure control (6,7) and the effects of 62 
bipolar disorder treatments on the level of inositol phosphates (19,74). These findings were 63 
successfully translated to mammalian disease models (7,19,60). Dictyostelium was also used to 64 
identify targets for compounds involved in bitter tastant detection (50,71) and conserved roles of 65 
homologues of human proteins (38,50), to investigate mitochondrial disease (25), Huntington’s 66 
disease (73) and centrosomal organisation and function (29,66). These studies suggest that 67 
Dictyostelium can inform our understanding of cellular function relevant to human disease.  68 
Dictyostelium has previously been employed to investigate the role of Ino1 in cell function (24), 69 
where insertional mutagenesis of ino1 produced an inositol auxotrophic phenotype with a 70 
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concomitant decrease in inositol trisphosphate. Here, we independently deleted a key region of 71 
the ino1 gene in an isogenic cell line, and find that growth of the ino1- mutant can only be partially 72 
rescued by exogenous inositol, suggesting a non-biosynthetic role for the protein. We further 73 
show that the previously described ‘inositol-less death’ is likely to lead to an upregulation of 74 
autophagy, loss of substrate adhesion and reduced cytokinesis resulting from inositol depletion. 75 
We also show that inositol depletion leads to a generalised reduction of phosphoinositide levels, 76 
without gross changes in metabolic profile. Surprisingly, we show that the greatest metabolic 77 
change is caused by loss of Ino1, and not by inositol depletion per se, since broad metabolic 78 
changes are not rescued by exogenous inositol, suggesting distinct effects of Ino1 loss and inositol 79 
depletion on cellular function. Finally, we identified a range of potential Ino1 binding partners, 80 
and confirmed direct Ino1 binding to a protein with mammalian homologues that serve as 81 
adaptors involved in the attachment to macromolecular complexes, providing a potential link to 82 
regulating inositol-independent cellular functions.  83 
 84 
Materials and Methods 85 
Materials - Axenic medium and LowFlo medium was purchased from ForMedium Co. 86 
Ltd (Hunstanton, UK). All restriction enzymes and First Strand cDNA synthesis kit were 87 
purchased from Fermentas (St Leon-Rot, Germany). Trizma hydrochloride (Tris-HCl), sodium 88 
chloride (NaCl), ethylenediaminetetraacetic acid (EDTA), 4′,6-diamidino-2-phenylindole 89 
(DAPI), cyclic adenosine monophosphate (cAMP), potassium phosphate monobasic (KH2PO4), 90 
potassium phosphate dibasic (K2HPO4), myo-inositol, and methanol were purchased from Sigma 91 
(Dorset, UK). The High Pure RNA isolation kit was purchased from Roche (Welwyn Garden 92 
City, UK). Penicillin-streptomycin and blasticidin were purchased from Life Technologies 93 
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(Gibco, UK). The DNasefree kit was purchased from Ambion (Austin, TX). The anti-RFP 94 
antibody was purchased from ChromoTek (Planegg-Martinsried, Germany).  95 
Cell culture, strains and plasmids - All Dictyostelium axenic strains were grown at 22 °C in 96 
Axenic medium (Formedium Co. Ltd) containing 100 μg/ml penicillin and 100 μg/ml 97 
streptomycin. Dictyostelium transformants with a disrupted ino1 gene were cultured in axenic 98 
medium with 10 µg/ml blasticidin and 500 μM myo-inositol.  99 
Knock-out constructs were created by amplifying 5′ and 3′ fragments within the ino1 gene by 100 
PCR from AX2 genomic DNA. The 5′ and 3′ PCR fragments were cloned into the pLPBLP 101 
expression vector (21), using BamHI-PstI and NcoI-KpnI restriction sites, respectively. The 102 
knock-out cassette was transformed into wild-type (AX2) cells and transformants were selected 103 
in axenic medium containing blasticidin (10 μg/ml). Independent clones of transformants resistant 104 
to blasticidin were screened for homologous integration by PCR. Loss of gene transcription was 105 
confirmed by reverse transcription PCR. For this purpose, RNA was extracted from the 106 
independent clones using the High Pure RNA isolation kit (Roche) according to the 107 
manufacturer's instructions. Contaminating DNA was removed using the DNasefree kit, followed 108 
by cDNA synthesis using the First Strand cDNA synthesis kit with 1 μg of RNA per sample. The 109 
cDNA was analysed by PCR to confirm loss of gene transcription (primers: 110 
GCTGCAAATCAAAAGGATCGTGCC and AAGGTGTTTTGTGGTGAACCATTGATG).  111 
The Ino1-RFP overexpression construct was prepared using the full-length ino1 (gene ID: 112 
DDB_G0285505) open reading frame. The gene was amplified from genomic DNA using EcoRI 113 
and BamHI as flanking restriction sites (primers: 114 
GAGCGAATTCATGTCAGCACAAATGTTTGAATC and 115 
TATGGATCCTAATCTTTGTTCTAATAACATG). The PCR products were cloned into an 116 
mRFPmars expression vector (389-2) under the control of the actin15 promoter (courtesy of 117 
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DrAnnette Müller-Taubenberger (1,23)). Constructs were transformed into the ino1- cell line by 118 
electroporation and selected for neomycin resistance (10 μg/ml). Expression of Ino1-RFP was 119 
confirmed by fluorescence microscopy and western blot analysis using anti-RFP antibodies. ino1 120 
gene expression was confirmed using reverse transcription PCR using the same method as 121 
described for generating an ino1 knock-out cell line. 122 
Development assays and cell image acquisition - Filter assays were used to develop Dictyostelium 123 
cells as described previously (74). Briefly, cells grown in the presence or absence (24 hours) of 124 
inositol (500 µM) were harvested in log-phase growth, and 1 × 107 cells/ml were plated on a 47 125 
mm nitrocellulose filter (Millipore, Watford, UK). Filters were incubated for 24 hours at 22°C 126 
prior to imaging.  127 
Substrate adhesion assay - ino1- or Ino1-RFP-expressing ino1- cells grown in HL5 media in the 128 
presence of inositol (500 µM) were plated into 6-well plates, and the medium was replaced with 129 
HL5 media in the absence or presence of inositol (500 µM). After 24 hours the medium was 130 
gently removed with an aspirator to dispose of the non-adherent cells. Fresh medium was added 131 
and cells were immediately re-suspended and counted, and the processes was repeated for later 132 
timepoints.  133 
Chemotaxis, Autophagy, and Cytokinesis assays - Chemotaxis assays were carried out using a 134 
Dunn chamber (Hawksley, Sussex, UK) as previously described (49). Images were recorded 135 
every 15 seconds over a 15 min period. Autophagy was measured in ino1- cells transformed with 136 
the atg8-GFP construct (Dictybase.org) (46). Cells were grown in Axenic medium with shaking 137 
for 72 hours (- inositol condition had inositol removed for 24 hours prior to the experiment), with 138 
16 hour incubation in LoFlo medium (Formedium) to reduce the background autofluorescence. 139 
Cytokinesis defects were measured in cells cultured in shaking suspension for 72 hours, and 140 
inositol was removed where indicated 24 hours before the start of an assay, and cells were fixed 141 
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with 100% methanol at −20°C for 15 minutes, prior to labelling with 4′,6-diamidino-2-142 
phenylindole (DAPI).  143 
Immunoprecipitation - Initial co-immunoprecipitations were performed with the ino1- cell line 144 
constitutively expressing the ino1-RFP gene; ino1- cells constitutively expressing the mRFPmars 145 
gene on its own was used as a control (for 2 of 3 repeats) or wild-type (Ax2) cell lysate as a 146 
control. The presence of Ino1-RFP and RFP was confirmed by western blot analysis with anti-147 
RFP antibodies. The gel was stained with Coomassie blue dye and the protein bands specific to 148 
Ino1-RFP (and absent in the RFP control) were evaluated by mass spectrometry and the data was 149 
analysed using Scaffold3 software.  150 
The ino1- cell line co-transformed with ino1-RFP construct and FLAG-gpmA, FLAG-pefB, or 151 
FLAG-Q54IX5 was used to perform a co-immunoprecipitation with anti-RFP coated beads to 152 
examine a direct interaction between Ino1 and these proteins. Ino1-GpmA and Ino1-Q54IX5 153 
interactions were detected by western blot analysis with anti-RFP and anti-FLAG antibodies. The 154 
ino1- cell line co-transformed with the ino1-RFP construct and either GFP-gpmA or GFP-Q54IX5 155 
was used to perform co-immunoprecipitation with anti-GFP coated beads to confirm a direct 156 
interaction between Ino1 and these proteins; ino1- cells co-expressing mRFPmars and either 157 
GFP-gpmA or GFP-Q54IX5 was used as a control for these experiments. The Ino1-Q54IX5 158 
interaction was confirmed by western blot analysis with anti-GFP and anti-RFP antibodies.  159 
Cells (3 x 108 per experiment) were washed with phosphate buffer, treated with 2.5 mM caffeine 160 
for 20 min with shaking, and lysed ( (0.5% NP40, 40 mM Tris-HCl, 20 mM NaCl, 5 mM EGTA, 161 
5 mM EDTA, 10 mM DTT, 1 mM PMSF, 2x protease and 2x phosphatase cocktail inhibitor 162 
(Roche – cat no. 11836170001 and 04906837001) on ice and the lysate was incubated with RFP-163 
Trap or GFP-Trap agarose beads (ChromoTek GmbH) as per manufacturer’s instructions. Briefly, 164 
the lysate was incubated with the beads for 1 hour at 4°C, then collected and washed twice (10 165 
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mM Tris-HCl, 150 mM NaCl, 0.5 mM EDTA, 1 mM PMSF, 2x protease and 2x phosphatase 166 
cocktail inhibitor (Roche)). The non-bound fraction was collected after this step. 167 
Immunocomplexes were dissociated from the beads by incubating at 70°C for 10 min in 4x 168 
TruPAGE LDS Sample Buffer (Sigma, PCG3009) and collected by centrifugation (the bound 169 
fraction) prior to the SDS-PAGE electrophoresis using either Sigma TruPAGE or BioRad pre-170 
cast gel system. Protein presence was detected with anti-GFP [3H9] or anti-RFP [5F8] antibodies 171 
(ChromoTek GmbH), or a monoclonal anti-FLAG M2 antibody (Sigma, F3165), and recorded 172 
using the Odyssey Sa infrared imaging system.  173 
NMR Spectrometry - Freeze-dried cell pellets were resuspended in 1 mL of Water/Methanol (1:2) 174 
and vortexed for polar metabolite extraction. Samples were then centrifuged at 2,400 g for 5 min 175 
and supernatants were kept for drying using a vacuum concentrator for 4.5 h at 45 °C. Once dried, 176 
samples were resuspended in 80 μL of phosphate buffer (in 90 % D2O and 0.05 % sodium 3-(tri-177 
methylsilyl) propionate-2,2,3,3-d4 (TSP) as a 1H NMR reference) and 50 μL of the solution was 178 
transferred into 1.7 mm capillary NMR tubes. Spectra were acquired at 300ºKon a Bruker Avance 179 
DRX 700 MHz NMR Spectrometer (Bruker Biopsin, Rheinstetten, Germany) operating at 700.19 180 
MHz and equipped with a CryoProbe™ from the same manufacturer. All spectra were acquired 181 
using a 1-dimensional noesy pulse sequence [recycle delay – 90º - t1 – 90º - tm – 90º - acquire 182 
free induction decay (FID)] with water suppression applied during RD of 2 s, a mixing time (tm) 183 
of 100 ms and a 90º pulse set at 7.70 μs. For each spectrum, 512 scans were accumulated over a 184 
spectral width of 9803.9 Hz, and all FIDs were multiplied by a broadening line function of 0.3 185 
Hz prior to Fourier transformation. All spectra were manually phased, baseline-corrected and 186 
calibrated to the TSP standard at δ 0.000 using the software MestReNova© (version 10.0.1, 187 
Mestrelab Research S.L., Spain). 188 
Phospholipid Analysis - Glycerophospholipid levels were analysed by mass spectroscopy as 189 
previously described (9). 190 
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RESULTS 191 
Ino1 protein is conserved from Dictyostelium to humans - To investigate the role of the 192 
Dictyostelium Ino1 protein, we first compared the Dictyostelium (Q54N49) and human 193 
(Q9NPH2-1) protein sequences (Fig 1B,C). The proteins share 59% sequence identity throughout 194 
their length, are of similar size and show common conserved NAD-binding and catalytic domains 195 
(Fig 1B) that are present in Ino1 proteins from species across distant biological kingdoms (Fig 196 
1C), suggesting a highly conserved catalytic role of Ino1 throughout evolution and supporting the 197 
use of Dictyostelium to analyze Ino1 function. 198 
ino1- is an inositol auxotroph - To analyse the effect of Ino1 loss and inositol depletion on 199 
Dictyostelium cell growth and development, we ablated 19% of the ino1 coding sequence, 200 
including two regions encoding highly conserved amino acid motifs, by homologous integration 201 
of a knockout cassette (Fig 1B-F). The resultant ino1- cells were unable to grow in liquid medium 202 
without inositol supplementation above 50 µM (Fig 2A), consistent with that shown previously 203 
(24). However, unlike this previous study, inositol supplementation did not fully restore the ino1- 204 
growth rate to that of the wild-type, reaching a maximal level of growth at 300 µM with higher 205 
concentrations not increasing growth.  206 
In Dictyostelium, starvation triggers cell differentiation and morphogenesis to form spore-bearing 207 
fruiting bodies. We thus investigated the effect of Ino1 loss, with and without inositol 208 
supplementation, on multicellular development. Wild-type and ino1- cells were starved on 209 
nitrocellulose filters for 24 hours, and fruiting body morphology was recorded (Fig 2B). ino1- 210 
cells grown in the absence of inositol for 24 hours prior to nutrient deprivation were able to 211 
aggregate but formed aberrant fruiting bodies (Fig 2B), a phenotype not observed for ino1- cells 212 
in an earlier report (24); however, inositol supplementation (500 µM) prior to the assay enabled 213 
ino1- cells to produce mature fruiting bodies with wild-type morphology.  214 
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Both growth and development phenotypes were due to lack of the Ino1 protein. This was shown 215 
by expression of Ino1 linked to a C-terminal red fluorescent protein (RFP) tag in ino1- cells, which  216 
restored wild-type growth and development with the resulting functional protein showing a 217 
cytosolic localisation (Fig 2 D,E,F,G). Interestingly, since exogenous inositol did not fully restore 218 
the wild-type growth rate in ino1- cells, it is likely that cells require the Ino1 protein for normal 219 
growth. ino1- cells were also unable to grow on a bacterial lawn (Fig 2G), as reported previously 220 
(29), even with inositol supplementation. These results confirm a vital role of inositol in 221 
Dictyostelium growth and development, consistent with that shown in a variety of organisms 222 
throughout the kingdoms of life (40).  223 
Ino1 loss triggers inositol depletion - Our data show that a block in cell growth and altered 224 
development results from the removal of exogenous inositol in the ino1- mutant, and thus we 225 
quantified inositol levels by NMR in the ino1- and wild-type cells in the presence or absence of 226 
added inositol (Fig 3A). Wild-type cells grown in un-supplemented medium contained 1.5 ± 0.1 227 
µM inositol, and this significantly increased to 3.4 ± 0.1 µM following inositol supplementation 228 
(p < 0.0001), and returned to baseline following removal of inositol (Fig 3A). In contrast, ino1- 229 
cells grown with inositol supplementation had an intermediate level of inositol (1.8 ± 0.1 µM) 230 
that significantly decreased to 0.8 ± 0.1 µM following removal of exogenous inositol for 12 hours 231 
(p = 0.0013). A reduced level was maintained following 24 hour starvation (1.2 ± 0.1 µM), and 232 
returned to 2.0 ± 0.1 µM following re-introduction of inositol (Fig 3B). These data confirm that 233 
in ino1- cells, inositol was depleted following withdrawal of exogenous inositol, and this trend is 234 
consistent with that reported earlier (24). In addition, this data suggests that the ino1- mutant 235 
supplemented with inositol has similar intracellular inositol levels to wild-type cells (without 236 
supplementation), and that differences between these cell types are likely to arise from an absence 237 
of the enzyme, enabling a range of experiments to provide new insights into the distinct cell and 238 
metabolic changes caused by inositol depletion and loss of Ino1.  239 
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Ino1 loss causes a pleiotropic phenotype - We first investigated potential changes in cell 240 
movement during chemotaxis toward cAMP (Fig 3B). In these experiments, wild-type cells 241 
showed a velocity of 9.63 ± 1.49 µm/min, with an elongated shape (aspect), and tendency for 242 
single directional movement (directness) of 0.87 ± 0.14. Loss of Ino1, without inositol depletion, 243 
caused a significant loss of elongated shape, suggesting an Ino1-dependent change. In contrast, 244 
inositol depletion in ino1- cells significantly reduced cell speed, whilst the loss of shape that was 245 
also observed for Ino1 deletion was retained, and showed increased persistence. These data 246 
suggest distinct effects specific to Ino1 loss (related to loss of cell shape) and to inositol depletion 247 
(loss of velocity). 248 
We then examined the mechanism leading to the block in cell growth caused by loss of Ino1 in 249 
the absence of exogenous inositol, previously termed ‘“inositol-less death” (56). Since autophagy 250 
can lead to cell death in response to cell stress or nutrient depletion (34), we tested whether 251 
inositol depletion triggered an autophagic response. In Dictyostelium, formation of 252 
autophagosomes can be visualised by the incorporation of a fluorescently-tagged autophagy-253 
related protein 8 (Atg8) into autophagosomal membranes (46). The ino1- strain, grown in the 254 
absence of inositol for 24 hours (but without nutrient depletion), showed a four–fold increase in 255 
autophagosome number per cell compared to the wild-type strain (Fig 3C,D). These data suggest 256 
that inositol depletion triggered an autophagic response in ino1- cells. 257 
We also examined the effect of Ino1 loss and inositol depletion on substrate attachment and 258 
cytokinesis. To assess changes in cell adhesion, the number of cells attached to plates was 259 
quantified up to 72 hours following the removal of exogenous inositol from the ino1- mutant. In 260 
the presence of inositol (500 µM), ino1- cells proliferated up to 24 hours and remained adherent 261 
(Fig 3E). Upon removal of exogenous inositol, ino1- cell number decreased to 88.5% of inositol-262 
supplemented cells after 24 hours, and to 33.5% after 72 hours. ino1- cells expressing ino1-RFP 263 
did not lose adhesion in the absence of exogenous inositol. Secondly, we assessed cytokinesis by 264 
 12 
 
comparing the number of nuclei per cell in the ino1- and wild-type strains, in the presence of 265 
inositol or following inositol depletion, using DAPI nuclear stain (Fig 3F,G) (47). In these 266 
experiments, ino1- cells showed a significant (p < 0.001) increase in nuclei number following 267 
inositol depletion compared to the wild-type strain. Under inositol depletion conditions, 24.7% 268 
of the ino1- cells accumulated ≥ 3 nuclei compared to 7.7% of the wild-type cells. This effect was 269 
rescued by growing ino1- cells in the presence of inositol (500 µM) (9.7% of cells accumulated ≥ 270 
3 nuclei) or by overexpressing ino1-RFP (Fig 3F,G) (10% of cells accumulated ≥ 3 nuclei). These 271 
data suggest that inositol depletion leads to an increase in autophagy, a loss of cell-substrate 272 
adhesion and a reduction in cytokinesis, but loss of Ino1 per se did not trigger these responses. 273 
Inositol depletion regulates phospholipid levels - Since inositol is a precursor to a family of 274 
inositol phospholipids (Fig 4A, B), we examined changes in phospholipid levels due to both the 275 
loss of Ino1 and as a result of inositol depletion. In Dictyostelium, two types of phospholipids are 276 
present, diacyl phospholipids containing two acyl linkages to the glycerol backbone, and the 277 
recently reported ether/acyl phospholipids containing a glycerol backbone linked to a fatty 278 
alcohol at position 1 (9) (Fig 4A). We quantified the levels of both phospholipid species in wild-279 
type and ino1- cells grown in the presence and absence of inositol (Fig 4C-Q). Separation of 280 
distinct phospholipid species was limited to those of different molecular weights. We first 281 
examined levels of the phospholipid precursor phosphatidic acid (PA), which comprises a 282 
glycerol backbone and two fatty acid tails. Both diacyl-linked and ether-linked PA levels 283 
decreased during early inositol depletion in ino1- cells (Fig 4C,D). Phosphatidylinositol (PI), 284 
which is formed by the addition of the inositol head group to PA, decreased following inositol 285 
depletion (in ino1-), with the greatest reduction seen in diacyl-linked PI (Fig 4E,F,). A similar 286 
effect was seen for the diacyl phosphatidylinositol monophosphate (PIP) (Fig 4G,H). 287 
Surprisingly, inositol depletion induced a reduction in diacyl phosphatidylinositol bisphosphate 288 
(PIP2) but not in ether/acyl PIP2 (Fig 4I,J). For phosphatidylinositol trisphosphate (PIP3), only 289 
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ether/acyl PIP3 was detectable in ino1- cells, and was reduced compared to wild-type cells, 290 
independent of exogenous inositol supply (Fig 4K). The reintroduction of inositol for 12 hours 291 
after 24 hour starvation restored the levels of the majority of ether/acyl and diacyl phospholipids. 292 
These data suggest that the pool of diacyl phospholipids is more sensitive to inositol depletion 293 
than ether/acyl species, and that cellular ether/acyl PIP2 levels are maintained during these 294 
conditions. 295 
Since a reduction in inositol synthesis attenuates the production of phosphoinositides, and causes 296 
a transient reduction of PA, we then monitored changes in other phospholipids during inositol 297 
depletion and rescue. No change in phosphatidylserine (PS) was seen in wild-type cells under any 298 
condition tested; however, ino1- cells depleted of inositol for 24 hours  showed a non-significant 299 
increase in PS that was further elevated following inositol replenishment for both ether/acyl and 300 
diacyl species (Fig 4L,M). Other phospholipids, containing ethanolamine and choline head 301 
groups, did not change in wild-type or ino1- cells under any condition (Fig 4N-Q). 302 
Ino1 loss causes a shift to catabolic metabolism - We next investigated the metabolic 303 
consequences of both the loss of Ino1 and inositol depletion using wild-type and ino1- cells grown 304 
in the presence and absence of inositol (Fig 5). Both ablation of ino1 and inositol treatment 305 
induced specific metabolic changes. Principal component (PC) analysis of metabolic profiles 306 
suggested that the greatest metabolic change was observed between the wild-type and ino1- cells 307 
independent of exogenous inositol provision (Fig 5A,B), where ino1 ablation accounted for 53% 308 
of the total variance as observed in PC1. The mutation resulted in an increase in amino acids and 309 
compounds related to amino acid breakdown (alanine, aspartate, isoleucine, lysine, methionine, 310 
GABA, putrescine), in energy-related metabolites (fumarate, lactate), in adenosine 311 
phosphorylated derivatives (5’-AMP, 3’-AMP, ATP, cAMP) and in sn-glycero-3-phosphocholine 312 
(GPC), a potent osmolyte (Fig 5B). In contrast, inositol treatment accounted for only 12% of the 313 
variance between the metabolic profiles of wild-type and ino1- cells as observed in PC2 (Fig 314 
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5A,C). In ino1- cells, inositol treatment resulted in increased amino acid levels (leucine, 315 
methionine, tyrosine). These data suggest a dominant role for the presence of the Ino1 protein 316 
(rather than inositol levels) in metabolic regulation (Fig 5). 317 
Ino1 absence caused a major shift in metabolic profile, and we therefore specifically examined 318 
changes caused by Ino1 loss (Fig 6A,B). This analysis showed changes in many of the metabolic 319 
products found in the initial PC analysis. In contrast to a loss of Ino1, inositol depletion caused 320 
limited changes to metabolic profiles. Here we specifically compared ino1- cells grown in the 321 
presence or absence of inositol (12 and 24h treatments were combined since they resulted in 322 
similar metabolic changes and inositol levels) (Fig 6C,D) to show that inositol supplementation 323 
led to an increase of inositol and lipids, consistent with the phosphoinositide analysis (Fig 4). 324 
Interestingly, reintroduction of inositol for 12 hours after 24 hour inositol depletion changed the 325 
metabolic profile of ino1- cells (Fig 6E,F).  326 
Supervised analysis was then used to specifically evaluate the impact of Ino1 loss on cell 327 
metabolism (Fig 7). This approach suggested that Ino1 loss was associated with a significant 328 
increase in some amino acids (alanine, aspartate, glycine, GABA, isoleucine, lysine, methionine), 329 
and in metabolites associated with regulation of the cell cycle and DNA metabolism (guanosine, 330 
ATP, deoxy-ADP, 5’AMP, 3’AMP, UTP, and β-alanine, a biomarker of the degradation of 331 
pyrimidines (17)). Putrescine was also significantly increased, consistent with a reduction in cell 332 
proliferation, as previously demonstrated in Dictyostelium  (35). An increase in lactate was also 333 
observed, which suggests an increase in the NADH+H+/NAD+ ratio that stimulates the activity 334 
of the lactate dehydrogenase. An increase in NADH+H+/NAD+ ratio would simultaneously 335 
inhibit the citrate synthase and slow down the Krebs cycle, resulting in an accumulation of some 336 
intermediates. This is consistent with the accumulation of acetate, derived from the spontaneous 337 
hydrolysis of oxaloacetate, and of fumarate and succinate, two other intermediates of the Krebs 338 
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cycle. Finally, sn-glycero-3-phosphocholine (GPC) was greatly increased, suggesting that the 339 
lack of Ino1 was compensated by the production of a strong osmolyte. The increased 340 
NADH+H+/NAD+ ratio is a signature of catabolic reactions. Together, these data suggest that the 341 
loss of Ino1 shifts cells into a catabolic state. Together with the observation of markers of reduced 342 
cell proliferation, these data further support the autophagic phenotype of ino1- mutants, even 343 
when supplemented with inositol. 344 
Supervised analysis was also used to evaluate the impact of inositol depletion on individual 345 
metabolites (Fig 7). This approach suggested that inositol depletion resulted in changes in some 346 
amino acids (increases in alanine, GABA, glycine, and valine, and a decrease in phenylalanine), 347 
an increase in lactate, fumarate, and succinate, and a decrease in 3’AMP, guanosine, and 348 
glycogen. No effect on the metabolic profile was shown due to the selection antibiotic 349 
(blasticidin) for the ino1- cells (O-PLS model parameters: R2Y = 0.18 and Q2Y = 0). Although 350 
we observed that the mutants were already in a catabolic state, the addition of inositol tended to 351 
moderate this metabolic phenotype, since indicators of anabolism (glycogen and lipids) were 352 
higher in cells supplemented with inositol, while those not supplemented were associated with 353 
markers of catabolism (i.e. lactate and succinate). Thus, these results suggest that the absence of 354 
Ino1, rather than inositol depletion, triggered broad metabolic changes.  355 
Mutation of an Ino1 catalytic residue reduces growth, independent of exogenous inositol - To 356 
investigate a role for Ino1 that is independent of catalytic activity, we expressed a mutated Ino1 357 
lacking a key catalytic aspartic acid (D342A) that is conserved throughout the tree of life (40). 358 
Wild-type cells expressing this construct showed strongly reduced growth, either in the presence 359 
or absence of inositol (500 µM; Fig 8A), suggesting a dominant negative effect of the protein. 360 
ino1- cells expressing this construct retained the inositol auxotrophic phenotype, confirming a 361 
lack of catalytic activity of the mutated protein, but additionally showed strongly reduced growth 362 
in the presence of inositol (500 µM).  363 
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Ino1 binds a possible macromolecular complex linker protein - To investigate a mechanism for 364 
Ino1 in regulating cell function independent of catalytic activity, Ino1 binding partners were 365 
isolated by co-immunoprecipitation. Ino1-RFP was expressed in ino1- cells, bound to agarose 366 
beads coated with anti-RFP antibody, and Ino1 binding proteins were purified by co-367 
immunoprecipitation, followed by separation by SDS-PAGE and identification by mass 368 
spectrometry (Fig 8B). This approach identified 104 potential binding partners from three 369 
independent experiments. Potential binding partners were divided into six major groups: actin-370 
related, immunity and stress, metabolism, nucleic acid related (translation, transcription, 371 
regulation of gene expression and DNA recombination), protein catabolism, modification and 372 
transport, and others encompassing signal transduction, ATP hydrolysis and proton transport 373 
(including V-type proton ATPase catalytic subunits A and B) (Supplementary data). We extended 374 
our analysis for three potential Ino1 binding proteins: GpmA, a phosphoglycerate mutase protein; 375 
PefB, a penta-EF hand domain-containing protein; and Q54IX5, an uncharacterised protein with 376 
three Sel1-like repeats (Fig 8C,D). These proteins tagged with a FLAG epitope were co-expressed 377 
in cells with Ino1-RFP, and Ino1-RFP was immunoprecipitated from cell lysates with RFP 378 
antibody linked to agarose beads. The bound protein fractions were then analysed for the presence 379 
of each FLAG-tagged protein, demonstrating that GpmA-FLAG bound weakly, whereas 380 
Q54IX5-FLAG bound strongly to Ino1-RFP (Fig 8C). The Q541X5-Ino1 interaction was 381 
confirmed using the reverse approach, where Q54IX5-GFP was coexpressed with Ino1-RFP, and 382 
immunoprecipitated with a GFP antibody linked to agarose beads; co-immunoprecipitated Ino1-383 
RFP was detected by Western blot with an RFP antibody (Fig 8D). These approaches confirmed 384 
that Q54IX5 binds strongly to Ino1.  385 
DISCUSSION 386 
Inositol and inositol-containing compounds are vital cellular components, and a range of studies 387 
have identified pleiotropic effects of inositol depletion on cell function, but have not considered 388 
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complications due to altered levels of the biosynthetic enzyme, Ino1. To distinguish between the 389 
effects of inositol depletion and a loss of Ino1 on cell function and metabolism, we ablated the 390 
inositol biosynthetic enzyme, Ino1, in Dictyostelium, and compared wild-type cells and cells 391 
without Ino1 in the presence and absence of inositol. Loss of Ino1 produced an inositol auxotroph 392 
phenotype during growth and blocked development, confirming an earlier Dictyostelium study 393 
(24), and results from diverse organisms ranging from Saccharomyces cerevisiae (13) to mice 394 
(45), demonstrating the essential conserved role of inositol in cellular function. We show that the 395 
myo-inositol levels decreased in the ino1- mutant by 36-56% (depending upon starvation time), 396 
and return to pre-depletion levels following inositol replenishment. This inositol depletion 397 
response is consistent with an obligate role for inositol production catalysed by Ino1. We show 398 
that inositol depletion resulting from ino1 ablation blocks development, reduces cell velocity, 399 
upregulates autophagy, and inhibits cytokinesis, consistent with a range of studies in other 400 
systems (12, 24, 37, 51, 62), and confirming the validity of this model to study Ino1 function. All 401 
of these phenotypes, except growth and cell shape, are rescued by provision of exogenous inositol, 402 
and are thus likely to be due to inositol depletion rather than loss of Ino1.  403 
Dysregulation of inositol levels has been reported in a wide range of biomedical and clinical 404 
studies, relating to both disease conditions and as a result of medicinal treatment, although few 405 
studies have addressed specific changes in Ino1 protein levels. A range of structurally 406 
independent bipolar disorder drugs, including carbamazepine, valproate and lithium, act via an 407 
inositol depletion mechanism (74), and induce autophagy in vitro and in vivo (43,67), most likely 408 
as a mechanism to promote survival by recycling cellular components (12,51). Altered inositol 409 
levels have also been demonstrated in patient studies of bipolar disorder (58), major depressive 410 
disorder  (10), and schizophrenia (59). For these reasons, modulating inositol levels was proposed 411 
as a therapy in the treatment of bipolar disorder (8), depression, and panic disorders  (48). In 412 
addition, Ino1 activity and protein levels are elevated in post-mortem brains of Alzheimer’s 413 
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patients (57), although studies showed pathologically-lowered inositol levels and mitochondrial 414 
dysfunction in mouse models of Alzheimer’s disease (68) that could be linked to autophagy (36). 415 
However, no distinction has been made in these studies between altered inositol levels and altered 416 
Ino1 levels. In our present study, we have separated the effects caused by altered Ino1 levels and 417 
inositol depletion, to provide a unique approach to monitor cellular and metabolic changes 418 
relating to inositol levels. 419 
Since phosphoinositide production is the first step of inositol incorporation into cell signalling, 420 
we examined the effect of loss of Ino1 and inositol depletion and replenishment on this family of 421 
chemicals, analysing both diacyl-linked and ether/acyl-linked compounds independently (9). 422 
Inositol depletion induced a rapid reduction in both species of PI and PIP, and strongly reduced 423 
diacyl PIP2 levels, but had little effect on ether/acyl PIP2. Surprisingly, PIP3 was greatly reduced 424 
in the ino1- mutant, under all conditions, independent of exogenous inositol. Overall, the greater 425 
reduction in diacyl-phosphoinositides may be due to these phospholipids comprising under 5% 426 
of the inositol phospholipids (9), leading to rapid metabolism. Alternatively, these compounds 427 
may provide a more labile signalling component compared to ether-derived compounds, and 428 
further research could investigate these alternatives. Nevertheless, this data shows a critical effect 429 
of inositol depletion in regulating phosphoinositides.  430 
These results also support studies demonstrating an important role for diacyl PIP2 in vesicle 431 
formation and transport  (32) and in membrane trafficking at the neuronal synapse (11).  In 432 
Dictyostelium, ablation of a PIP2 biosynthetic enzyme PIP5 kinase (PikI) led to a 90% reduction 433 
in PIP2 levels, and disorientated cell movement (22). The pivotal role of PIP2 in these processes 434 
suggests a requirement for cells to maintain the levels of this essential molecule during inositol 435 
starvation. Cytokinesis, the final part of the cell division process, is also critically dependent upon 436 
an increase in PIP2 levels (37). Our analysis shows a 65% reduction in diacyl PIP2 levels 437 
following 24-hour inositol depletion, and is consistent with this phospholipid playing a critical 438 
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role in cytokinesis, as evidenced by the multinucleate phenotype of ino1- cells. In a similar 439 
manner, PIP2 is involved in substrate attachment by regulating actin polymerisation and 440 
depolymerisation (37) that may result in a reduced cell-substrate adhesion. Overall, the data 441 
suggest that inositol depletion has a fundamental and rapid effect on phosphoinositide regulation 442 
that is likely to result in wide-ranging changes in cellular function and cell health.  443 
Interestingly, Ino1 may play a role in regulating PIP3 levels regardless of inositol level, since the 444 
ino1- mutant grown in inositol-supplemented medium showed reduced PIP3 levels, even though 445 
intracellular myo-inositol levels were comparable to those of wild-type cells. Previous studies in 446 
Dictyostelium demonstrated that a complete block in PIP3 production, by deletion of all five type-447 
1 phosphoinositide 3-kinase enzymes, resulted in poor growth in suspension and developmental 448 
defects (27). Combined, these findings suggest that loss of the Ino1 protein leads to a loss of PIP3 449 
production, resulting in poor cell growth.  450 
We also examined metabolic changes caused by loss of the Ino1 protein and during inositol 451 
depletion. Surprisingly, the greatest metabolic change observed here was due to an absence of 452 
Ino1, independent of the inositol level, which gave rise to elevated amino acids, energy-related 453 
components, DNA regulation and osmolytes. This metabolic shift was not due to altered inositol 454 
levels per se, since cellular inositol levels are consistent between the mutant and wild-type cells 455 
during inositol supplementation, but rather an absence of the Ino1 protein. These changes are 456 
likely to have a major effect on cellular function, and suggest an important non-catalytic role for 457 
the protein in metabolic regulation. We thus propose a key role for Ino1 in regulating metabolism 458 
through an inositol homeostasis-independent mechanism, and that ino1 ablation induces a shift 459 
in metabolism towards an autophagic response, consistent with increased levels of putrescine, 460 
amino acids and nucleotide derivatives (31). In contrast, inositol depletion caused general changes 461 
in lipids, and from the wide range of specific compounds assessed, variable changes in a few 462 
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amino acids were found. This suggests inositol depletion has little metabolic effect in the short 463 
timescale examined in this study.  464 
Since inositol supplementation did not fully restore ino1- growth, we expressed a mutant protein 465 
Ino1-D342A in these cells and assessed growth. This mutation is likely to disrupt catalytic activity 466 
and is conserved in all known Ino1 proteins. Expression of Ino1-D342A did not rescue the inositol 467 
auxotrophy resulting from Ino1 loss, and thus does not catalyse inositol biosynthesis. In contrast, 468 
expression of the protein reduced growth in all strains, independently of exogenous inositol 469 
provision. Further studies will be necessary to determine if this response is due to the depletion 470 
of the Ino1 substrate, inactivation of a potential Ino1 multimeric complex, or by other 471 
mechanisms.  472 
To identifying new roles for Ino1 in regulation of cellular function, we isolated a number of 473 
potential Ino1 binding partners. These included proteins related to cytoskeletal organisation, 474 
mitochondrial respiration chain, proton transport, DNA and protein regulation, and metabolism, 475 
including fatty acid, glycolysis and purine metabolism; these potential interactors are consistent 476 
with those identified in S. cerevisiae (63,64) and in humans (20). In addition, components of the 477 
peripheral V1 complex of the vacuolar ATPase were identified, which are responsible for 478 
acidifying intracellular compartments in eukaryotic cells, and these have also been identified as 479 
Ino1 interactors in S. cerevisiae (16). From the list of potential binding partners, we independently 480 
confirmed Ino1-GpmA binding, where GpmA is involved in the interconversion of 2- and 3-481 
phosphoglycerate, and 2,3-bisphosphoglycerate (2,3 BPG) is a potent inhibitor of InsP3 5’-482 
phosphatase and also InsP2 dephosphoryation (70) and is elevated following ino1 loss in 483 
Dictyostelium (24). We also confirmed strong Ino1-Q54IX5 binding, where this protein contains 484 
a tetratricopeptide repeat (TPR) that mediates protein-protein interactions, often during the 485 
assembly of multiprotein complexes (5). Although the function of an Ino1-Q54IX5 interaction 486 
remains to be examined, the potential human orthologue of Q54IX5 is the SEL1L protein that is 487 
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involved in the movement of misfolded proteins from the ER to the cytosol (44), and thus 488 
deregulation of this protein in the ino1- mutant may have far-reaching effect on cell metabolism.  489 
Since we show that the absence of Ino1 and inositol depletion have different molecular and 490 
metabolic effects, we question whether these effects are interrelated. Inositol depletion has been 491 
shown to activate ino1 expression in a wide range of models (55,69), including Dictyostelium 492 
(74), and mice (54); this effect is likely to elevate Ino1 levels. Many studies have relied on using 493 
inositol depleting drugs prescribed as bipolar disorder treatments, which act through multiple 494 
targets (28,53,65,75), and hence these results are likely to be complicated by secondary effects. 495 
In contrast, our studies did not utilise drug treatments, and our results suggest that short-term 496 
inositol depletion does not cause large metabolic changes in Dictyostelium, with a resulting 497 
increase in ino1 transcription acting to reverse this deficit (74). This responsive regulation would 498 
protect cells against a transient reduction in inositol levels without triggering large metabolic 499 
changes. However, a dysregulation of this responsive mode, resulting from a reduction of Ino1 500 
levels, is likely to cause wide-ranging metabolic effects, independent of inositol provision. 501 
Our studies show that a loss of the crucial inositol biosynthetic enzyme Ino1 and inositol depletion 502 
cause discrete cellular, molecular and metabolic effects. Although inositol depletion alters cell 503 
physiology, triggering an autophagic response, loss of substrate adhesion, reduction in cell 504 
division, and a rapid reduction in a range of phospholipids, it does not trigger a large change in 505 
metabolic profile. In contrast, the Ino1 protein itself plays an important role in cell growth and 506 
shape and metabolic regulation, regardless of inositol level, including the binding to a linker 507 
protein, Q54IX5, suggesting further roles of this protein.508 
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FIGURE 1. Inositol Signalling, and the Conservation of the Ino1 Protein in Dictyostelium 769 
and Humans. (A) Inositol metabolism. Ino1 converts glucose 6-phosphate to inositol-3-770 
phosphate, which is a rate-limiting step in inositol production. (B) Sequence homology 771 
between the human (Q9NPH2-1) and Dictyostelium (Q54N49) Ino1 is present throughout the 772 
proteins. Identical amino acids are shown in dark blue. The NAD binding and catalytic domains 773 
are among the four regions that are highly conserved in eukaryotic Ino1 proteins: GWGGNNG 774 
(yellow), LWTANTERY (blue), SYNHLGNNDG (green) and NGSPQNTFVPGL (purple). 775 
The tetramerisation domain containing a putative catalytic site (with the conserved amino acid 776 
residues SYNHLGNNDG) is shown in red. The amino acids that were ablated in Dictyostelium 777 
Ino1 are shown by the horizontal black line. (C) Alignment of the conserved regions of Ino1 778 
proteins from various species, where ‘*’ denotes identity, ‘:’ high conservation, ‘.’ low 779 
conservation levels. (D) Schematic representation of the strategy used to prepare the ino1 780 
knock-out construct. N- and C-terminal portions of the ino1 gene were cloned into knock-out 781 
vector flanking blasticidin resistance (bsr) gene and the knock-out cassette was transformed 782 
into Dictyostelium cells, where homologous recombination deleted a portion of the ino1 gene 783 
and disrupts the open reading frame. (E) PCR screening strategy to identify ino1- mutants, 784 
showing primers locations for genomic and vector controls, the diagnostic knock-out product, 785 
and spanning the inserted bsr gene present in the ino1- knock-out. (F) PCR results showing the 786 
ablation of part of the ino1 gene in the ino1- mutant, in comparison to wild-type cells. INO1 - 787 
inositol 3-phosphate synthase; IMPase - inositol monophosphatase; IPPase - inositol 788 
polyphosphate 1-phosphatase; IP2 - inositol bisphosphate; IP3 - inositol trisphosphate; PLC - 789 
phospholipase C; PI – phosphatidylinositol; PIP - phosphatidylinositol phosphate; PIP2 - 790 
phosphatidylinositol bisphosphate; PIP3 - phosphatidylinositol trisphosphate. 791 
 792 
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FIGURE 2.  Ablating ino1 in Dictyostelium Causes Inositol Auxotrophy. (A) Dictyostelium 793 
cells grown in liquid medium show rapid growth up to a stationary phase (at 168h). Ablation 794 
of ino1 blocks cell growth in the absence of exogenous inositol, with only partial restoration 795 
of wild-type growth by the addition of either 300M or 500 M inositol. (B) During starvation, 796 
wild-type Dictyostelium forms fruiting bodies without inositol pre-treatment. Under the same 797 
conditions, ino1- cells are unable to form fruiting bodies. Fruiting body formation in ino1- cells 798 
is restored when the cells are grown with inositol supplementation prior to the assay. (C) 799 
Expressing ino1-RFP in Dictyostelium ino1- cells was confirmed by reverse transcription PCR 800 
(RTPCR); with an Ig7 gene control, and Western blot analysis to show the full length protein 801 
(with a ladder in kDa), that (D) restores growth rate  and (E) is present in the cytosol and (F) 802 
restores development in the absence of exogenous inositol. (G) ino1- cells are unable to grow 803 
on agar plates seeded with bacteria, and expressing ino1-RFP in these cells restores bacterial 804 
growth. Error bars represent SEM. Statistical significance was determined by an unpaired two-805 
tailed t-test, ***p < 0.001; n = 3. 806 
 807 
FIGURE 3. Inositol Depletion Causes a Change in Velocity and Cell Shape, an Activation 808 
of Autophagy, a Loss in Cell-Substrate Adhesion and a Reduction in Cytokinesis in 809 
Dictyostelium ino1- Cells. (A) The level of myo-inositol analysed by NMR in the wild-type 810 
and ino1- cells grown with (500 µM) or without exogenous inositol for 12 or 24 hours, or 811 
following inositol re-introduction. Inositol levels were reduced in the ino1- mutant following 812 
inositol depletion for 12 and 24 hours, and restored to basal levels following reintroduction for 813 
12 hours. (B) Average velocity, aspect and persistence of aggregation-competent ino1- cells 814 
(grown with 500 µM inositol, or without inositol, for 24 hours prior to imaging) or wild-type 815 
cells during chemotaxis towards cAMP. Velocity shows the distance travelled by cells over 816 
time. Aspect refers to the roundness of cells (1 = perfectly round). Directness is a ratio of the 817 
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distance travelled by a cell compared to the total direct distance, where 1 represents a straight 818 
line. (D) Autophagosomes were visualised in wild-type and ino1- cells expressing Atg8-GFP 819 
and (E) quantified in the presence or absence (24 hours) of inositol treatment.  (F) Cell adhesion 820 
was monitored in wild-type and ino1- cells, and in ino1- cells expressing ino1-RFP, in the 821 
presence (500 µM) and absence of inositol for at least 24 hours. (G) Cytokinesis was examined 822 
in wild-type and ino1- cells, and in ino1- cells expressing ino1-RFP, using DAPI nuclear stain 823 
to label cell nuclei, and (H) the number of nuclei per cell was quantified. Error bars represent 824 
SEM. Statistical significance was determined by (A&B,C,E,F) an unpaired two-tailed t-test, 825 
(H) 2-way ANOVA with Bonferroni post-test, *p < 0.05, ***p < 0.001; (C) n ≥ 25 cells 826 
analysed per condition; (E) n ≥ 117 cells analysed per condition; (F) n = 3 repeats; (H) n ≥ 250 827 
cells analysed per condition. 828 
 829 
FIGURE 4. Inositol Depletion Affects Phosphoinositides Levels in Dictyostelium. (A) The 830 
structure of phosphoinositol showing diacyl or ether/acyl fatty acid linkages to a glycerol 831 
backbone and inositol head group. (B) Metabolic pathway depicting phospholipid production 832 
from phosphatidic acid (PA) as an example. (C-Q) To monitor phospholipids in wild-type and 833 
the ino1- mutant, cells were grown in the presence of inositol (500 µM, denoted ‘+’), the 834 
absence of inositol (12 or 24h; denoted ‘+/-‘) or with inositol added after a 24h depletion period 835 
(500 µM for 12h; denoted ‘+/-/+‘) and control denotes without inositol supplementation. The 836 
levels of ether/acyl (C34:1ea) or diacyl (C36:3aa) phospholipids are shown as a percentage 837 
relative to phospholipid levels present in the wild-type strain grown in the absence of inositol. 838 
Inositol depletion reduced the levels of diacyl PI, PIP and PIP2 phosphoinositides; the level of 839 
PIP3 was undetectable, and reduced the levels of ether/acyl PIP and PIP3. Error bars represent 840 
SEM. Statistical analysis was carried out between wild-type (+ inositol) and ino1- (+ inositol) 841 
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by unpaired two-tailed t-test to illustrate the significance of changes due to the loss of the Ino1 842 
protein, shown as “*”, *p < 0.05, **p < 0.01, ***p < 0.001.  843 
 844 
FIGURE 5. Comparison of Metabolic Profiles of Dictyostelium Following Ino1 Loss and 845 
Inositol Depletion. To monitor metabolic profiles in the wild-type and the ino1- mutant, cells 846 
were grown in the presence of inositol (500 µM, denoted ‘+’), the absence of inositol (12 or 847 
24h; denoted ‘+/-‘) or in inositol added after 24h depletion period (500 µM for 12h; denoted 848 
‘+/-/+‘), and control denotes without inositol supplementation. (A) Metabolic variations 849 
existing between cell type and myo-inositol exposure were assessed by principal component 850 
analysis (PCA) generated from the 1H-NMR spectra of the Dictyostelium metabolic 851 
fingerprints. The main source of variation (53%) was driven by the mutation while inositol 852 
depletion accounted for approximately 12% of the metabolic variation in this dataset. (B) 853 
Loadings plot associated with PC1 (red peaks pointing upwards are positively associated with 854 
PC1 while those pointing downwards are negatively associated with PC1). (C) Loadings plot 855 
associated with PC2.  856 
 857 
FIGURE 6. Metabolic profile analysis of the ino1- mutant. Cells were grown in the presence 858 
of inositol (500 µM, denoted ‘+’), the absence of inositol (12 or 24h; denoted ‘+/-‘) or in 859 
inositol added after 24h depletion period (500 µM for 12h; denoted ‘+/-/+‘). (A,B) Metabolic 860 
changes induced by ino1 ablation. Orthogonal projection to latent structure discriminant 861 
analysis (O-PLS DA) was used in order to determine the specific impact of the mutation on 862 
cell metabolism. (A) Plot of the scores against the cross-validated scores generated by the O-863 
PLS DA (R2Y = 0.89, Q2 = 0.88 and p value for 500 random permutations = 0.002) using the 864 
1H-NMR spectra of the Dictyostelium wild-type and ino1- cells (except +/-24/+12h inositol 865 
exposure) as a matrix of independent variables and mutation as predictor. (B) Loadings plot of 866 
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the O-PLS DA model (peaks in red indicate increased metabolite levels in response to the 867 
mutation). (C,D) Effect of inositol treatment on the metabolism of the ino1- mutant.  (C) Plot 868 
of the scores against the cross-validated scores generated by the O-PLS DA (R2Y = 0.67, Q2Y 869 
= 0.51 and p value for 500 permutations = 0.002) using the 1H-NMR spectra of the ino1- cells 870 
(-12h and -24h inositol vs + inositol) as a matrix of independent variables and depletion of 871 
myo-inositol as a predictor. (D) Loadings plot of the O-PLS DA model (peaks in red indicate 872 
increased metabolite levels in response to the presence of inositol). (E,F) Reintroduction of 873 
myo-inositol post deprivation induces a metabolic shift. (E) Plot of the scores against the cross-874 
validated scores generated by the O-PLS DA (R2Y= 0.90, Q2Y = 0.86 and p value for 500 875 
permutations = 0.002) using the 1H-NMR spectra of the ino1- cells (-12h and -24h inositol vs 876 
+/-/+ inositol) as a matrix of independent variables and myo-inositol reintroduction as a 877 
predictor. (F) Loadings plot of the O-PLS DA model (peaks in red indicate increased metabolite 878 
levels in response to the depletion of myo-inositol), n ≥ 4.  879 
 880 
FIGURE 7. Levels of metabolites in wild-type and ino1- cells grown under varying inositol 881 
conditions. Metabolite levels, measured by NMR, were quantified using MATLAB and plotted 882 
to illustrate changes observed in wild-type and ino1- cells for (A) amino acids (B) cell cycle 883 
and DNA-related metabolites (C) other metabolites. Control denotes without inositol 884 
supplementation. Error bars represent SEM. Statistical analysis was carried out between wild-885 
type (Ax2) (+ inositol) and ino1- (+ inositol) by unpaired two-tailed t-test to illustrate the 886 
significance of changes due to the loss of Ino1 protein, shown as “*”, *p < 0.05, **p < 0.01, 887 
***p < 0.001. A separate unpaired two-tailed t-test analysis was used to compare ino1- (+ 888 
inositol) and ino1- (- inositol 12h and 24h), shown as “+”, +p < 0.05, ++p < 0.01, +++p < 0.001. 889 
 890 
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FIGURE 8. An Ino1 non-catalytic role in Dictyostelium. (A) Ino1-RFP protein with an 891 
aspartic acid to alanine substitution (ino1D342A) in a highly conserved region of a catalytic 892 
domain was overexpressed in the wild-type and ino1- cells. In the ino1- cells, the mutated 893 
protein was unable to rescue the ino1- inositol auxotrophy, consistent with a catalytically 894 
inactive protein. In the wild-type cells, expressing the mutant protein significantly decreased 895 
growth, while the addition of exogenous inositol partially rescued this phenotype. Error bars 896 
represent SEM for n = 3 repeats. Statistical analysis was carried out for each individual 897 
condition compared to wild-type (Ax2) by unpaired two-tailed t-test, *p < 0.05, ***p < 0.001. 898 
(B) Co-immunoprecipitation of the Ino1-RFP protein (or RFP only control) expressed in ino1- 899 
cells, using anti-RFP coated beads, shown for bound (B) and non-bound fractions (NB). SDS-900 
PAGE gels were visualised following Coomassie staining (left) and analysed by Western blot 901 
with an anti-RFP antibody (right). Bands specific to Ino1-RFP (and absent from the RFP 902 
control) were analysed by mass spectrometry to identify potential Ino1 binding partners. (C) 903 
FLAG-tagged potential interacting proteins GpmA, PefB, and Q541X5, were investigated by 904 
immunoprecipitation using Ino1-RFP and anti-RFP-coated beads, followed by Western blot 905 
analysis with anti-RFP and anti-FLAG antibodies. (D) An Ino1-Q54IX5 interaction was 906 
confirmed by immunoprecipitation of the GFP-Q54IX5 protein with anti-GFP-coated beads in 907 
the presence of Ino1-RFP (or RFP only) and Western blot analysis with anti-RFP and anti-GFP 908 
antibodies.  909 
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